Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRB-ONC1
- Development stage
- Unknown
- Lead developer
- Transpire Bio
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
TRB-ONC1 is a novel, synthetic inhaled formulation of cannabidiol (CBD) being developed by Transpire Bio for the treatment of glioblastoma (GBM). Delivered via inhalation, the therapy leverages Transpire Bio's proprietary inhalation technology platforms to target the central nervous system directly, aiming to minimize systemic adverse effects while delivering therapeutic concentrations to the brain. In October 2025, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to TRB-ONC1 for the treatment of glioblastoma.
- Other names
- Inhaled synthetic CBD formulationsynthetic inhaled cannabidiol formulation
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on TRB-ONC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRB-ONC1.